The combination of a strong Q1 beat, raised full-year guidance, and FDA approval for the aura6000 OSA system creates a powerful catalyst. The OSA market entry with a differentiated device (no contraindication for complete concentric collapse) could drive significant long-term growth. Monitor the upcoming conference call for initial commercialization plans and reimbursement strategy for aura6000.
Price Chart
Executive Summary
LivaNova reported Q1 2026 revenue of $362.3M (+14.3% YoY reported, +11.1% constant-currency), beating consensus of $346.1M. Adjusted diluted EPS of $0.98 exceeded the consensus estimate of $0.90 by 8.9%. The company raised full-year 2026 guidance: revenue growth raised 100bps to 7-8% constant-currency and adjusted EPS raised $0.05 to $4.20-$4.30. Additionally, the FDA granted premarket approval for the aura6000 System for obstructive sleep apnea, a significant new product catalyst.
Key Financial Metrics
Key Facts
- Q1 2026 revenue $362.3M, +14.3% reported / +11.1% constant-currency YoY, above $346.1M consensus
- Q1 2026 adjusted diluted EPS $0.98, vs $0.90 consensus (beat by 8.9%)
- Raised FY2026 revenue growth guidance to 7.0%-8.0% constant-currency (from 6.0%-7.0%)
- Raised FY2026 adjusted EPS guidance to $4.20-$4.30 (from $4.15-$4.25)
- FDA premarket approval received for aura6000 System for moderate-to-severe obstructive sleep apnea
- Cardiopulmonary revenue +18.3% reported (+14.0% constant-currency); Neuromodulation +9.3% reported (+7.6% constant-currency)
- Adjusted operating income $71.1M, up from $64.6M in Q1 2025
- Adjusted free cash flow $3.8M in Q1 2026
Financial Impact
Revenue beat of ~$16.2M vs consensus; EPS beat of $0.08 vs consensus; guidance raised for both revenue and EPS
Risk Factors
- OSA market entry is still early-stage; commercialization and reimbursement timelines uncertain
- GAAP operating income declined to $41.5M from $48.6M due to higher R&D spending ($58.7M vs $37.9M) for OSA investments
- Adjusted free cash flow was only $3.8M, down from prior periods, though this is seasonally low
- 3T Heater-Cooler litigation and SNIA environmental liabilities remain overhangs
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001639691-26-000031 |
| Document: livn-20260506.htm | 0001639691-26-000031 |
| Document: 0001639691-26-000031-index-headers.html | 0001639691-26-000031 |
| Document: 0001639691-26-000031-index.html | 0001639691-26-000031 |
| Document: 0001639691-26-000031.txt | 0001639691-26-000031 |
| 8-K Data (Synthetic) | 0001639691-26-000031 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | Insider Cluster | $79.47 $78.49 | ▼ −1.23% | ▼ −3.34% | $75.07 (−5.54%) |
Aug 5, 2026 8w ago | 8-K | $78.15 $80.78 | ▲ +3.37% | ▲ +3.02% | $75.07 (−3.93%) |
May 6, 2026 21w ago | 8-K | $66.26 $71.75 | ▲ +8.29% | ▲ +7.15% | $75.07 (+13.30%) |
Apr 29, 2026 22w ago | DEFA14A | $58.92 $66.26 | ▲ +12.46% | ▲ +9.35% | $75.07 (+27.41%) |
Feb 25, 2026 31w ago | 8-K | $70.29 $65.26 | ▼ −7.16% | ▼ −6.06% | $75.07 (+6.80%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access